Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480

Many tyrosine kinase inhibitors (TKIs) have failed to reach human use due to insufficient activity in clinical trials. However, the failed TKIs may still benefit patients if their other kinase targets are identified by providing treatment focused on syndromes driven by these kinases. Here, we search...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Gudernova, Iva, Balek, Lukas, Varecha, Miroslav, Kucerova, Jana Fialova, Kunova Bosakova, Michaela, Fafilek, Bohumil, Palusova, Veronika, Uldrijan, Stjepan, Trantirek, Lukas, Krejci, Pavel
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2017
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5752523/
https://ncbi.nlm.nih.gov/pubmed/29312610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22674
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים